시장보고서
상품코드
1441324

세계의 다발성 골수종 치료제 시장 규모, 점유율, 성장 분석, 치료 유형별, 유통 채널별, 산업 예측(2023-2030년)

Global Multiple Myeloma Therapeutics Market Size, Share, Growth Analysis, By Treatment type, By Distribution Channel - Industry Forecast 2023-2030

발행일: | 리서치사: SkyQuest | 페이지 정보: 영문 157 Pages | 배송안내 : 3-5일 (영업일 기준)

    
    
    


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

다발성 골수종 치료제 세계 시장 규모는 2022년 266억 9,000만 달러로 평가되었습니다. 2023년 284억 2,000만 달러에서 2031년에는 470억 4,000만 달러에 달하고, 예측 기간(2024-2031년) 동안 6.5%의 연평균 복합 성장률(CAGR)을 나타낼 전망입니다.

다발성 골수종 치료제 세계 시장은 최근 몇 가지 중요한 요인으로 인해 괄목할 만한 성장을 보이고 있습니다. 골수 기능을 파괴하고 형질세포의 비정상적인 증식과 뼈의 취약성을 유발하는 이 복잡한 혈액암은 인구 고령화와 세계 의료계의 분자 메커니즘에 대한 이해도가 높아짐에 따라 주목받고 있습니다. 과학 연구의 발전은 줄기세포 이식, 면역 조절제, 프로테아좀 억제제, 화학요법, 단일 클론 항체, 지지 요법 등 표적 치료법 개발의 길을 열었습니다. 제약회사들은 새로운 치료법과 개인 맞춤형 의료 접근 방식에 많은 투자를 하고 있으며, 이는 업계의 경쟁을 심화시키고 있습니다. 제약사, 생명공학 기업 및 연구기관의 협력으로 단클론 항체 및 CAR-T 세포 치료와 같이 효능이 향상되고 부작용이 감소된 혁신적인 치료법이 개발되어 치료 옵션에 큰 도약의 조짐을 보이고 있습니다.

목차

주요 요약

  • 시장 개요
  • 번영과 쇠퇴

조사 방법

  • 정보 조달
  • 2차/1차 정보원
  • 시장 규모 추정
  • 시장 전제조건과 제한

상위 시장 분석

  • 시장 개요
  • 시장 규모
  • 시장 역학
    • 성장 촉진요인
    • 기회
    • 성장 억제요인
    • 과제

주요 시장 인사이트

  • 기술 분석
  • 가격 분석
  • 공급망 분석
  • 밸류체인 분석
  • 시장 생태계
  • IP 분석
  • 무역 분석
  • 스타트업 분석
  • 원재료 분석
  • 혁신 매트릭스
  • 파이프라인 제품 분석
  • 거시경제 지표
  • 주요 투자 분석
  • 주요 성공 요인
  • 경쟁 정도

시장 역학과 전망

  • 시장 역학
    • 성장 촉진요인
    • 기회
    • 성장 억제요인
    • 과제
  • 규제 상황
  • Porter의 Five Forces 분석
  • 향후 혼란에 관한 특별 인사이트

세계의 다발성 골수종 치료제 시장 : 치료 유형별

  • 시장 개요
  • 화학요법 및 기타 약제
  • 기존 화학요법
  • 면역 조절제
  • 프로테아좀 억제제
  • Histone Deacetylase (HDAC) 억제제
  • 단클론항체
  • 방사선
  • 줄기세포 이식 및 지지 요법

세계의 다발성 골수종 치료제 시장 : 유통 채널별

  • 시장 개요
  • 소매 약국./드럭스토어
  • 병원 약국
  • 온라인 약국

세계의 다발성 골수종 치료제 시장 규모 : 지역별

  • 시장 개요
  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 독일
    • 스페인
    • 프랑스
    • 영국
    • 기타 유럽
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 한국
    • 기타 아시아태평양
  • 라틴아메리카
    • 브라질
    • 기타 라틴아메리카
  • 중동 및 아프리카
    • GCC 국가
    • 남아프리카공화국
    • 기타 중동 및 아프리카

경쟁 구도

  • 주요 5개사 비교
  • 주요 기업의 시장 포지셔닝(2021년)
  • 주요 시장 기업이 채택한 전략
  • 주요 성공 전략
  • 시장에서의 최근 활동
  • 주요 기업의 시장 점유율(2021년)

주요 기업 개요

  • Johnson & Johnson(미국)
  • Celgene Corporation(미국)
  • Amgen Inc.(미국)
  • Janssen Pharmaceuticals, Inc.(미국)
  • Bristol Myers Squibb Company(미국)
  • Onyx Pharmaceuticals, Inc.(미국)
  • Merck & Co., Inc.(미국)
  • Karyopharm Therapeutics Inc.(미국)
  • GlaxoSmithKline plc(영국)
  • Sanofi(프랑스)
  • Takeda Pharmaceutical Company Limited(일본)
  • Bluebird Bio, Inc.(미국)
  • Daiichi Sankyo Company, Limited(일본)
  • Genmab A/S(덴마크)
  • AbbVie Inc.(미국)
  • Seattle Genetics, Inc.(미국)
  • Novartis AG(스위스)
  • MorphoSys AG(독일)
  • Kite Pharma, Inc.(미국)
  • Millennium Pharmaceuticals, Inc.(미국)
  • PharmaMar, S.A.(스페인)
  • Celldex Therapeutics, Inc.(미국)
  • Kyowa Kirin Co., Ltd.(일본)
  • Poseida Therapeutics, Inc.(미국)
  • Glenmark Pharmaceuticals Ltd.(인도)
LSH 24.04.11

Global Multiple Myeloma Therapeutics Market size was valued at USD 26.69 billion in 2022 and is poised to grow from USD 28.42 billion in 2023 to USD 47.04 billion by 2031, growing at a CAGR of 6.5% in the forecast period (2024-2031).

The global market for multiple myeloma therapeutics has experienced remarkable growth in recent years, driven by several key factors. This complex hematological cancer, which disrupts bone marrow function and leads to abnormal plasma cell proliferation and bone fragility, has seen increased attention due to the aging population and a greater understanding of its molecular mechanisms within the global health community. Advances in scientific research have paved the way for the development of targeted therapies, including stem cell transplants, immunomodulatory drugs, proteasome inhibitors, chemotherapy, monoclonal antibodies, and supportive care measures. Pharmaceutical companies are heavily investing in novel treatments and personalized care approaches, intensifying competition in the industry. Collaborations between pharmaceutical firms, biotech companies, and research institutions have yielded innovative therapies with improved efficacy and reduced side effects, such as monoclonal antibodies and CAR-T cell therapies, heralding a significant leap forward in treatment options.

Top-down and bottom-up approaches were used to estimate and validate the size of the Multiple Myeloma Therapeutics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Multiple Myeloma Therapeutics Market Segmental Analysis

By Treatment type, the market is segmented into Chemotherapy and other drugs, Traditional chemotherapy, Immunomodulating agents, Proteasome inhibitors, Histone Deacetylase (HDAC) inhibitors, Monoclonal Antibodies, Radiation, Stem cell transplant and supportive treatment. Retail Pharmacies & Drug Stores, Hospital Pharmacies and Online Pharmacies are the market segments we end up with when division by distribution channel occurs. If we split the market by region, we will be left with the following sectors: North America, Middle East and Africa, Europe, Asia Pacific, and Latin America.

Drivers of the Multiple Myeloma Therapeutics Market

Advancements in Treatment Options have significantly propelled the multiple myeloma therapeutics market forward, with the introduction of innovative medications such as monoclonal antibodies, proteasome inhibitors, and immunomodulatory drugs (IMiDs). These novel therapies, designed to target cancer cells while minimizing harm to healthy cells, have substantially enhanced treatment efficacy, prolonged patient survival rates, and enhanced post-therapy quality of life. Additionally, the Growing Aging Population has contributed to the market's expansion, as older individuals are more susceptible to multiple myeloma, thus increasing demand for efficient treatment options

Restraints in the Multiple Myeloma Therapeutics Market

High Treatment Costs present a notable restraint, as some therapies remain prohibitively expensive, particularly in regions with limited access to healthcare or lower economic status, potentially limiting the adoption of advanced treatments. Moreover, the Complex Disease Characteristics of multiple myeloma, including its genetic and molecular heterogeneity, pose challenges in developing personalized treatment plans tailored to individual patient needs, which could impede the market's growth.

Market Trends of the Multiple Myeloma Therapeutics Market

Key Market Trends include the ongoing focus on Advancements in Targeted Therapies and Immunotherapies, aiming to minimize the side effects associated with traditional chemotherapy by directly targeting cancer cells. Additionally, there's a growing emphasis on Personalized Medicine and Biomarker-driven Approaches, leveraging genetic profiling and biomarkers to identify patient subgroups most likely to benefit from specific treatments, thus optimizing therapeutic outcomes.

Table of Contents

Executive Summary

  • Market Overview
  • Wheel of Fortune

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Parent Market Analysis

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges

Key Market Insights

  • Technology Analysis
  • Pricing Analysis
  • Supply Chain Analysis
  • Value Chain Analysis
  • Ecosystem of the Market
  • IP Analysis
  • Trade Analysis
  • Startup Analysis
  • Raw Material Analysis
  • Innovation Matrix
  • Pipeline Product Analysis
  • Macroeconomic Indicators
  • Top Investment Analysis
  • Key Success Factor
  • Degree of Competition

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Regulatory Landscape
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers
  • Skyquest Special Insights on Future Disruptions
    • Political Impact
    • Economic Impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Global Multiple Myeloma Therapeutics Market by Treatment type

  • Market Overview
  • Chemotherapy and other drugs
  • Traditional chemotherapy
  • Immunomodulating agents
  • Proteasome inhibitors
  • Histone Deacetylase (HDAC) inhibitors
  • Monoclonal Antibodies
  • Radiation
  • Stem cell transplant and supportive treatment

Global Multiple Myeloma Therapeutics Market by Distribution Channel

  • Market Overview
  • Retail Pharmacies & Drug Stores
  • Hospital Pharmacies
  • and Online Pharmacies

Global Multiple Myeloma Therapeutics Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • UK
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2021
  • Strategies Adopted by Key Market Players
  • Top Winning Strategies
    • By Development
    • By Company
    • By Year
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2021

Key Company Profiles

  • Johnson & Johnson (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Celgene Corporation (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Amgen Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Janssen Pharmaceuticals, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bristol Myers Squibb Company (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Onyx Pharmaceuticals, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck & Co., Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Karyopharm Therapeutics Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GlaxoSmithKline plc (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sanofi (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Takeda Pharmaceutical Company Limited (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bluebird Bio, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Daiichi Sankyo Company, Limited (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Genmab A/S (Denmark)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AbbVie Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Seattle Genetics, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • MorphoSys AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Kite Pharma, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Millennium Pharmaceuticals, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • PharmaMar, S.A. (Spain)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Celldex Therapeutics, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Kyowa Kirin Co., Ltd. (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Poseida Therapeutics, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Glenmark Pharmaceuticals Ltd. (India)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제